Trials / Completed
CompletedNCT01574235
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,114 (actual)
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivestim® |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2012-04-10
- Last updated
- 2015-07-28
Locations
87 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01574235. Inclusion in this directory is not an endorsement.